# Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

> **NCT00225017** · PHASE3 · COMPLETED · sponsor: **Northwestern University** · enrollment: 50 (actual)

## Conditions studied

- HIV Infection
- Hyperlipidemia

## Interventions

- **DRUG:** Atazanavir
- **DRUG:** current antiretroviral regimen

## Key facts

- **NCT ID:** NCT00225017
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225017, "Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00225017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*